Cell Biosciences develops instrumentation and reagent systems to bring analytical chemistry to biology. Cell Biosciences is focused on breakthrough protein assay capability with our first instrument platform scheduled for release within one year.
Cell Biosciences is commercializing instrumentation and reagent systems to bring analytics to biology. In the “post-genomic” age, new tools are in high demand to enable researchers to rapidly develop assays for specific proteins in complex biological samples. High priority needs include specific detection of protein variants, detection of low abundance proteins in small sample volumes and improved quantification and throughput. Cell Biosciences is focused on these priorities to deliver new technology that will be enabling in these areas. We anticipate launch of our first instrument platform in 2006.

Financials

Date Type Amount Investors Valuation
11/22/06 Series A -1M Unknown

People

Tim Harkness (The President and CEO)

Linda Cahill (President/CEO)

Roger O’Neill (VP of Development)

Peter Vander Horn (VP Engineering & Manufacturing)

Dick Rubin (Sr. Director of Marketing)

View more details about all 11 people at Cell Biosciences

News

Peter Thiel’s latest bets boost Siri clone and cancer therapy

April 17, 2013 8:08 pm

Paypal cofounder Peter Thiel doesn’t shy away from making risky bets in disruptive technology and research. Today, the Thiel Foundation… Continue reading ⟩

Calithera Biosciences brings in $10M for cancer therapeutics

July 17, 2010 6:17 am

Calithera Biosciences, a developer of small molecules that cause apoptosis, or death, of cancer cells, has secured $10 million of… Continue reading ⟩

Cell Biosci expands offerings with Protein Forest buy

December 8, 2009 5:27 pm

Cell Biosciences, maker of software and other tools used to determine how cells move and interact, has acquired Protein Forest,… Continue reading ⟩